Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

Background: Brain volume loss (BVL) has been identified as a predictor of disability progression in relapsing multiple sclerosis (RMS). As many available disease-modifying treatments (DMTs) have shown an effect on slowing BVL, this is becoming an emerging clinical endpoint in RMS clinical trials.

Methods: In this study, a systematic literature review was conducted to identify BVL results from randomized controlled trials of DMTs in RMS.